In addition to milestone and royalty payments to be paid to Nabi Biopharmaceuticals, Kedrion will assume development costs for the product candidate in both Europe and the US through at least phase II clinical trials.
Civacir is Nabi Biopharmaceuticals’ plasma-derived, polyclonal antibody product candidate, which, when approved, would be the first therapy for the prevention of the recurrence of hepatitis C-related liver disease in HCV-positive liver transplant recipients, or in patients who receive an HCV-positive liver.
“We believe that Civacir, if approved, would fill a critical and growing void in viable treatment options for HCV-positive liver transplant recipients and patients who receive an HCV-positive liver. We are looking forward to developing this clinically and commercially important product with Nabi Biopharmaceuticals,” said Paolo Marcucci, president and managing director of Kedrion.